Compound library-盟基生物科技股份有限公司

Inhibitor & Compound Library

Compound library

Compound library

Inhibitor & Compound Library

Compound library

一、產品介紹

盟基生物科技為Sellckchem的代理商,提供最完整的小分子藥物 (Small Molecule compounds / Inhibitors),其中超過3000種小分子抑制劑應用於細胞訊息傳遞路徑 (Cell Signaling Pathways);Selleckchem的screening library共有超過2100種小分子藥物經過生物學與藥理學活性驗證。在臨床前研究和臨床研究上,均證實其安全性和效率。其中包含了許多美國FDA認可的化合物,對您的學術研究提供可靠的數據和說服力。在2014年裡,就有2,352篇發表文獻使用Selleckchem的小分子抑制劑,只要跟隨Selleckchem的文獻指南,您可輕鬆掌握最新的科學資訊與動態,並且還有多篇文獻支持,絕對是小分子抑制劑的不二選擇。
圖一:SelleckChem包含許多不同路徑的小分子抑制劑之比例
 


二、訂購資訊

Cat. No Library Name Targets Include Description & Advantages
L3000 Anti-cancer Compound Library A unique collection of 386 anti-cancer compounds under clinical trials.  1. 12 types of cancers: Breast Cancer, Leukemia, Lung Cancer, Lymphoma, etc.
 2. Contains inhibitors of PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc. 3. Some compounds have been approved by the FDA.
L2900 Anti-diabetic Compound Library A unique collection of 32 small molecules affecting the development of diabetes. Targets including both type 1 and type 2 diabetes modulators: DPP-4, GPR, Potassium Channel, PPAR, SGLT, etc.
L3100 Anti-infection Compound Library A unique collection of 118 anti-infective small molecules with biological activity of antibiotics, antifungal drugs, anti-HIV, etc. Mainly include sulfonamides, aminoglycosides, tetracyclines and macrolides.
L3300 Apoptosis Compound Library A unique collection of 35 small molecules used for apoptosis research targeting Bcl-2, Caspase, p53, TNF-alpha, Mdm2, survivin, etc. Targets Bcl-2, Caspase, p53, TNF-alpha, Mdm2, survivin, etc.
L2600 Autophagy Compound Library A unique collection of 152 autophagy signaling pathway inhibitors. Targets Proteasome, HIF, HDAC, Aurora Kinase, Sirtuin, E3 Ligase, Calcium Channel, mTOR, etc.
L1700 Bioactive 1902 bioactive compounds. 1. Bioactivity and safety confirmed by preclinical research and clinical trials.
2. Some compounds have been approved by the FDA.
3. Includes APIs, natural products, and chemotherapeutic agents.
L2300 Cambridge Cancer  Compound Library A unique collection of 313 anti-cancer compounds. 1. A highly value-added library derived through a collaboration with researchers at the MIT Koch Institute.
2. Embraces the whole spectrum of cancer targets, from kinases to notch signaling, to metabolic targets.
L1900 Epigenetics Compound Library A unique collection of 128 small molecule modulators. Including Histone Deacetylase (HDACs), SIRTs, Lysine demethylases, Histone Acetyltransferases (HATs), DNA Methyltransferase (Dnmts), and SIRTs activators.
L1300 FDA-approved Drug Library A unique collection of 1018 FDA-approved drugs. 1. Locate new targets for old drugs.
2. Bioactivity and safety confirmed by clinical trials.
3. Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc.
L2200 GPCR Compound Library A unique collection of 254 small molecule compound library for GPCR screening. 1. 200 so-called orphan GPCRs are functionally unknown.
2. Including 5-HT receptor, dopamine receptor, opioid receptor, adrenergic receptors, cannabinoid receptor, mGluR, and ETA-receptor etc.
L1100 Inhibitor Library A unique collection of 1,224 inhibitors including PI3K, mTOR, Akt, GSK-3, VEGFR, EGFR, PDGFR and more. 1. Bioactivity and safety confirmed by preclinical research and clinical trials.
2. Some inhibitors have been approved by the FDA.
3. Targets PI3K, VEGFR, and RTK pathway, HDAC, Aurora kinase, CDK and cell cycle regulators, Integrase/Proteasome, Phosphatase etc.
L2700 Ion Channel Ligand Library A unique collection of 52 ion channel ligands. Targets ion channels such as calcium channel, potassium channel, sodium channel, GABA receptor.
L1200 Kinase Inhibitor Library A unique collection of 378 kinase inhibitors. 1. Bioactivity and safety confirmed by preclinical research and clinical trials.
2. Some inhibitors have been approved by the FDA.
3. Targets kinases such as RTKs, PI3K, Aurora Kinase, CDK, and MEK.
4. Most are ATP competitive.
L3400 MAPK Inhibitor Library A unique collection of 44 small molecule inhibitors used for MAPK signaling research. Targets MEK, Raf, p38 MAPK, JNK, ERK, etc.
L1400 Natural Product Library A unique collection of 131 natural products for high throughput screening and high content screening. 1. Structurally diverse, bioactive, and cell permeable.
2. Rich documentation with structure and IC50.
L2400 Pfizer Licensed Compound Library All 85 compounds are licensed by Pfizer and have been marketed or clinically proven bioactive. From anti-cancer compounds (Bosutinib) to a glycylcycline antiobiotic (Tigecycline) to combat the growing prevalence of antibiotic resistance.
L2800 PI3K/Akt Inhibitor  Library A unique collection of 98 PI3K signaling pathway inhibitors. Targets PI3K, mTOR, Akt, GSK, ATM/ATR, etc.
L2500 Protease Inhibitor Library A unique collection of 43 small molecule inhibitors used for chemical genomics. 1. Bioactivity and safety confirmed by preclinical research and clinical trials.
2. Targets proteasome, HCV Protease, DPP-4, Caspase, MMP, Gamma-secretase, Beta Amyloid.
L2100 Stem Cell Signaling Compound Library A unique collection of 81 small molecule inhibitors. Targets which modulate the function of stem cells such as Wnt, Notch, SMAD, and Hedgehog signaling
L3500 Target Selective Inhibitor Library A unique collection of validated bioactive compounds covering over 140 targets. 1. Selectivity is at least 100-fold higher relative to non-primary target(s).
2. Including PI3K/Akt, MAPK, PTK, JAK, apoptosis, and others.
L1800 Tyrosine Kinase Inhibitor Library  A unique collection of 141 tyrosine kinase inhibitors. 1. Bioactivity and safety confirmed by preclinical research and clinical trials.
2. Some tyrosine kinase inhibitors have been approved by FDA.
3. Targets tyrosine kinases such as Bcr-AbI, PDGFR, EGFR, VEGFR, SRC, c-Met and JAK, etc.